Advertisement
Home »

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.

Aug 14, 2023

ABOUT THE EXPERTS

  • Alberto Hernando-Calvo

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G2C4, Canada; Departamento de Medicina, Universidad Autónoma de Barcelona (UAB), 08035 Barcelona, Spain.

    Maria Vila-Casadesús

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Yacine Bareche

    Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC H2X0A9, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, QC H3T1J4, Canada.

    Alberto Gonzalez-Medina

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Farnoosh Abbas-Aghababazadeh

    Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada.

    Deborah Lo Giacco

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Agatha Martin

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Omar Saavedra

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Irene Brana

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Maria Vieito

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Roberta Fasani

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    John Stagg

    Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC H2X0A9, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, QC H3T1J4, Canada.

    Francesco Mancuso

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Benjamin Haibe-Kains

    Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada; Department of Computer Science, University of Toronto, Toronto, ON M5S2E4, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada; Vector Institute for Artificial Intelligence, Toronto, ON M5G1M1, Canada.

    Ming Han

    Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada.

    Roger Berche

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Trevor J Pugh

    Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G2C4, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada; Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada.

    Oriol Mirallas

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Jose Jimenez

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Nadia Saoudi Gonzalez

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Claudia Valverde

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Eva Muñoz-Couselo

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Cristina Suarez

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Marc Diez

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Elena Élez

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Jaume Capdevila

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Ana Oaknin

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Cristina Saura

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Teresa Macarulla

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Joan Carles Galceran

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Enriqueta Felip

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Rodrigo Dienstmann

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Philippe L Bedard

    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G2C4, Canada.

    Paolo Nuciforo

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Joan Seoane

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Josep Tabernero

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Elena Garralda

    Department of Medical Oncology, Vall D’Hebron University Hospital, 08035 Barcelona, Spain; Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain.

    Ana Vivancos

    Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain. Electronic address: avivancos@vhio.net.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement